Economic Burden of Rare Diseases With Common Diseases as a Comorbidity in Poland
- 20 October 2020
- journal article
- research article
- Published by University of Warsaw in Problemy Zarzadzania
- Vol. 2/2020 (88), 103-120
- https://doi.org/10.7172/1644-9584.89.6
Abstract
Purpose: Some of the common diseases are the comorbidities of rare diseases and they impose a considerable economic burden on the national health care system and economy. We examined the economic burden of a rare disease (tuberous sclerosis complex - TSC) in Poland and its comorbidities (common diseases - epilepsy and status epilepticus) while taking into account a sensitivity analysis. Design/Methodology/Approach: This study is a prevalence-based top-down cost of illness study that analyzes the direct and indirect cost of TSC and its complications. The research was based on the data obtained from the National Health Fund (hereinafter referred to as "NFZ", which is the abbreviation of the source language name of the institution), Social Insurance Institution (hereinafter referred to as "ZUS", which is the abbreviation of the source language name of the institution), and Poland's Central Statistical Office (hereinafter referred to as "GUS", which is the abbreviation of the source language name of the institution) by using the human capital method. Findings: The total cost of TSC and its complications in Poland, when taking the sensitivity analysis into account, amounts to EUR 2.2 million-EUR 3.4 million, which has a prevalence of indirect costs (61%-83% of the total costs). The conducted analysis indicates that the higher costs of common diseases result from insufficient financing for research of rare diseases which in many cases have common diseases as a comorbidity. Research limitations/implications: The limitations of the research analysis result from the lack of registration of patients suffering from rare diseases in Poland and from the requirements for the billing codes in the documentation of NFZ and Polish health care providers. Therefore, the study includes a sensitivity analysis. Originality/value: This is the first attempt to evaluate the total economic burden of TSC in Poland. The study indicates that the indirect costs of diseases are often overlooked in health care planning in Poland.Keywords
This publication has 28 references indexed in Scilit:
- An Intuitive Approach to Understanding the Attributable Fraction of Disease Due to a Risk Factor: The Case of SmokingInternational Journal of Environmental Research and Public Health, 2013
- Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complexEuropean Journal of Paediatric Neurology, 2011
- Cost-of-illness of patients with systemic sclerosis in a tertiary care centreRheumatology, 2010
- Cost of illness associated with Niemann-Pick disease type C in the UKJournal of Medical Economics, 2009
- Does depression increase the risk of developing type 2 diabetes?Occupational Medicine, 2007
- Tuberous sclerosis complex: Advances in diagnosis, genetics, and managementJournal of the American Academy of Dermatology, 2007
- Costs of on‐demand and prophylactic treatment for severe haemophilia in Norway and SwedenHaemophilia, 2004
- Prenatal screening for cystic fibrosis: an economic analysisHealth Economics, 2001
- On the Concept of Health Capital and the Demand for HealthJournal of Political Economy, 1972
- The pre-therapeutic classification of co-morbidity in chronic diseaseJournal of Chronic Diseases, 1970